Discover a study that also highlighted that treatment intensification with enzalutamide benefited patients regardless of ...

Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust ...

Astellas & Pfizer’s Xtandi shows long-term overall survival in metastatic hormone-sensitive prostate cancer: Tokyo Saturday, May 24, 2025, 13:00 Hrs [IST] Astellas Pharma Inc. a ...

This male cancer can be easily screened for, but the lack of symptoms in the early stages makes it easy to overlook.

Gilead Sciences, Inc. (NASDAQ:GILD) has revealed encouraging results from its ASCENT-03 clinical trial, showcasing a major ...

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...